Drug Database
CE

ceftriaxone sodium + tazobactam sodium (Citrafen)

✓ Approved

Bharat Serums and Vaccines Limited · Small Molecule · Small Molecule

What is ceftriaxone sodium + tazobactam sodium?

ceftriaxone sodium + tazobactam sodium is a small molecule developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesCitrafen
CompanyBharat Serums and Vaccines Limited
Drug ClassSmall Molecule
RouteInjectable (Others)
StatusApproved

Therapeutic Indications

ceftriaxone sodium + tazobactam sodium is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsStreptococcal infection✓ Approved

Related Research Articles

PubMedEuropean journal of sport science2026-07-25

Gastrointestinal Symptoms Associated With Sodium Bicarbonate Supplementation Protocols: A Systematic Review.

Winter Ian P IP, Sarac Paul P, Wilson Patrick B PB

Sodium bicarbonate positively impacts performance, but its associated gastrointestinal symptoms (GIS) may limit use. This systematic review synthesized literature that has evaluated GIS with sodium bicarbonate supplementation. Literature searches were performed from February 2024-March 2026. Eligible studies provided ≥ 5 g of sodium bicarbonate within a 24-h period or, if a multi-day protocol, at least one day involving ≥ 5 g. Included studies had a placebo group/condition or a comparison group/condition that created a contrast related to delivery method, form, or dose. In total, 101 investigations were summarized in six categories: acute single dosing (n = 35); acute spread dosing (n = 28); chronic dosing (n = 7); acute versus chronic dosing (n = 5); delivery form (n = 18); and other (n = 8). Existing literature suggests that common acute doses (0.2-0.4 g/kg) elicit mild-to-severe GIS, which likely increase in a dose-dependent manner when sodium bicarbonate is ingested in a single dose. Strategies to reduce GIS with acute dosing include spreading intake over hours, using enteric-coated capsules/tablets, and ingesting sodium bicarbonate mini-tablets within a carbohydrate hydrogel. Direct comparisons of these strategies to reduce GIS are absent in current literature; thus, ranking their effectiveness is not possible. Multi-day dosing may lessen GIS, but symptom documentation throughout supplementation periods is poorly characterized. Notably, 26 of 101 studies failed to perform inferential statistical testing to examine condition/group differences in GIS. Making definitive recommendations about sodium bicarbonate supplementation to minimize GIS remains challenging. Major needs remain for direct comparisons between protocols purported to reduce GIS and improvements in GIS data collection, reporting, and analysis.

PubMedDevelopmental medicine and child neurology2026-07-25

Seizure worsening and sodium-channel blockers in HCN1-related epilepsies: A case series.

PubMedEnvironmental research2026-07-25

Fabrication of a Tripolyphosphate-Modified Chitosan-Sodium Alginate Composite for Highly Efficient Uranium Adsorption from Water.

Zhong Xingyu X, Yang Fang F, Lu Lihong L, Zhang Wenqing W et al.

The preparation of composite materials with excellent adsorption capacity for uranium in water remains a topic of great interest. In this work, a novel composite adsorbent, tripolyphosphate-modified chitosan-sodium alginate (PCSSA), was successfully prepared by incorporating sodium alginate into tripolyphosphate-modified chitosan via chemical cross-linking. The resulting material exhibited excellent adsorption capacity for U(VI) in aqueous solutions. Within the chitosan matrix, amino, alkyl, and phosphate groups act synergistically to form amino-alkyl phosphate ligands (NH2-CH2-PO43-) with chelating functionality, providing abundant adsorption sites for efficient U(VI) removal. SEM and EDS characterization revealed a rugged, plate-like surface morphology, loaded with functional groups such as phosphate and carboxyl/hydroxyl groups. Systematic adsorption experiments indicated that the U(VI) adsorption behavior of PCSSA follows the Langmuir isotherm and the Elovich kinetic model. Under optimal conditions (pH = 3, 298.15 K, adsorbent dose = 30 mg), the maximum adsorption capacity reached 561.86 mg·g-1. In real water samples with a low U(VI) concentration (30 mg·L-1), the removal efficiency was as high as 88%, outperforming many similar bio-based adsorbents. FTIR and XPS analyses suggested that the phosphate groups interact with UO22+ through multiple mechanisms, including electrostatic attraction, ligand exchange, and complexation. The PCSSA composite is environmentally friendly and straightforward to prepare, showing promising potential for application in water pollution control.

PubMedInternational journal of biological macromolecules2026-07-25

Controlled release network hydrogel based on zein/sodium alginate-stabilized chrysanthemum essential oil Pickering emulsions for prolonged preservation of fresh-cut Gastrodia elata.

Zhang Lihui L, Liu Jieni J, Law Chung Lim CL, Sun Qing Q et al.

Browning and microbial proliferation are major factors driving quality deterioration in fresh-cut Gastrodia elata. This study developed a zein/sodium alginate-stabilized chrysanthemum essential oil (CEO) Pickering emulsion and incorporated it into gelatin-konjac glucomannan hydrogels for fresh-cut G. elata preservation. The emulsion exhibited nanoscale droplets (194.53-515.00 nm) with exceptional stability (zeta potential: -82.85 to -95.92 mV), confirming effective encapsulation of CEO. The optimized hydrogel (GK-8%) formed a dense network with uniform pore structure, demonstrating superior water retention and sustained release properties, achieving 73.30% CEO release over 390 h. Application tests revealed that GK-8% significantly reduced weight loss (≤ 0.15%) and browning index (26.72% reduction), maintained firmness and total phenolic content, while decreasing antioxidant enzyme activities, indicating reduced oxidative stress. Visual observations showed that GK-8% treatment delayed visible browning by approximately 3 days compared to the control. The hydrogel extended shelf life through synergistic effects of microbial inhibition and oxidative stress alleviation, providing an effective, eco-friendly strategy for fresh-cut product preservation.

PubMedIndian journal of clinical biochemistry : IJCB2026-07-25

Short-Chain Fatty Acids Ameliorates Lipid Profile, Oxidative Stress and Inflammation in Letrozole Induced Polycystic Ovary Syndrome Rat Model.

Acharya Ashwitha A, Shetty Prasanna Kumar PK, Sonkusare Shipra S, Padmanabha Ganeshkodi Roopashree R et al.

Polycystic ovary syndrome (PCOS) is one of the most common metabolic-reproductive disorders affecting reproductive-age women, causing an irregular menstrual cycle, hyperandrogenism, and polycystic ovarian morphology. Current therapies for PCOS focus on the management of symptoms. Short-chain fatty acids (SCFAs) play a significant role in PCOS by influencing the gut microbiota composition and metabolic pathways. The impact of short-chain fatty acids (SCFAs) on lipid profiles, inflammatory markers, and oxidative stress parameters in the PCOS model remains unclear. The present study aimed to elucidate the effect of SCFA on lipid profile, oxidative stress parameters, and inflammation in a high-fat diet-fed letrozole-induced PCOS model. 48 Female albino Wistar rats were randomised to 8 group (n = 6). The groups were treated with letrozole to induce PCOS and then treated with sodium acetate (SA), sodium propionate (SP), sodium butyrate (SB), and SCFA (3:1:1) mixture. This study observed a significant distortion in lipid profile, oxidative stress parameters and inflammatory markers. Our data showed, PCOS model showed elevated levels of triglycerides and very-low-density lipoprotein, which were significantly ameliorated when treated with SCFA (3:1:1), SA, SP, and SB. SP, SB, and SCFA (3:1:1) significantly lowered total cholesterol, while only SB and SCFA (3:1:1) significantly lowered low-density lipoprotein-cholesterol. Elevated high-density lipoprotein-cholesterol was observed in the SA, SB, and SCFA (3:1:1) treated group. The malondialdehyde level was lowered in the SCFA-treated groups, whereas the total antioxidant capacity, superoxide dismutase, and glutathione level was elevated. Our data showed a significant reduction in IL-6, IL-1β levels in the PCOS-induced group treated with SA, SP, SB, and SCFA (3:1:1). The findings of the present study suggest that short-chain fatty acids restructure dyslipidemia, oxidative stress and inflammation in a PCOS-induced model, highlighting their possible role as therapeutic dietary supplements in alleviating PCOS.

PubMedMolecular diagnosis & therapy2026-07-25

Development of a Point-of-Care Recombinase Polymerase Amplification Assay for Detection of Neisseria gonorrhoeae and Ceftriaxone-Resistance Associated penA Allele 60.001.

Sun Xia X, Fu Ying Y, Liu Yi Y, Liu Qiongyao Q et al.

Neisseria gonorrhoeae is a global public health threat, exacerbated by the rapid dissemination of ceftriaxone-resistant strains harboring penA allele 60.001. Current diagnostics are limited by long turnaround times, reliance on thermal cycling equipment, and poor suitability for resource-limited settings. We developed an isothermal recombinase polymerase amplification assay coupled with a lateral flow strip (RPA-LFS) for separate identification of N. gonorrhoeae and the ceftriaxone resistance-associated SNP C932T (A311V) in penA 60.001 and limited closely related alleles. Species detection employed an RPA-Nfo probe targeting the conserved porA pseudogene. Resistance detection employed an allele-specific amplification refractory mutation system RPA (ARMS-RPA) strategy, incorporating artificial mismatches to specifically discriminate the C932T SNP. Assay performance was evaluated using genomic DNA of a panel of gonococcal and non-gonococcal strains and validated directly on unprocessed clinical urine samples. The porA RPA-LFS assay demonstrated a detection limit of 30 fg of genomic DNA with no cross-reactivity against closely related Neisseria species or other bacterial pathogens. The mismatch penA 60.001 RPA-LFS assay achieved a detection limit of 300 fg and exhibited absolute analytical specificity, with no amplification observed from wild-type or other mosaic penA alleles. Validation using 50 clinical urine samples yielded 100% concordance (95% CI: 92.9-100%) with gonorrhoea identification by reference nucleic acid amplification tests, with 100% sensitivity (95% CI: 87.1-100%) and 100% specificity (95% CI: 85.7-100%), and 100% concordance (95% CI: 85.7-100%) with resistance allele detection, with 100% sensitivity (95% CI: 67.6-100%) and 100% specificity (95% CI: 79.6-100%). This integrated RPA-LFS platform provides rapid detection of gonococcal infections and ceftriaxone resistance without requiring a thermal cycler, delivering visual results within 20 minutes. The assay represents a promising point-of-care solution for timely diagnosis, targeted antibiotic therapy, and resistance surveillance in resource-limited settings, though further validation on diverse specimen types and integration of an internal amplification control are needed.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ceftriaxone sodium + tazobactam sodium